Clinical cases in osteoporosis

Versions

PDF (Español (España))
Texto (Español (España))

Keywords

Osteoporosis
Osteoporosis en el hombre
Inhibidores de aromatasa
Salud ósea Osteoporosis
Male osteoporosis
Aromatase inhibitors
Bone health

How to Cite

Rivera Martínez, W. A., & Castaño Ceballos , P. A. . (2023). Clinical cases in osteoporosis. Interdisciplinary Journal of Epidemiology and Public Health, 5(2), e–9881. https://doi.org/10.18041/2665-427X/ijeph.2.9881 (Original work published December 30, 2022)

Abstract

Introduction: Osteoporosis is defined as a “systemic disorder characterized by low bone mass and microarchitectural deterioration, with the consequent increase in bone fragility and greater susceptibility to fractures.

Objective: Present two cases of interest in the approach to osteoporosis, resolving the main questions that arise in their intervention.

Results: Initially, an elderly male is described who underwent diagnosis and management in the context of pathological fractures and later a postmenopausal female patient with a history of breast cancer under management with aromatase inhibitor and predisposition to associated fractures.

Conclusion: The decrease in bone quality in special populations such as men and women exposed to aromatase inhibitors requires, in order to prevent fractures, that risk factors and possible secondary causes be controlled from the beginning of follow-up. The initiation of antiresorptive/osteoformative management if indicated changes the prognosis of the disease and the outcomes.

https://doi.org/10.18041/2665-427X/ijeph.2.9881
PDF (Español (España))
Texto (Español (España))

References

Bliuc D, Nguyen ND, Milch VE, Nguyen T V., Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513-21. doi: 10.1001/jama.2009.50

Salari N, Ghasemi H, Mohammadi L, Behzadi M Hasan, Rabieenia E, Shohaimi S, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1): 609. Doi: 10.1186/s13018-021-02772-0

Golds G, Houdek D, Arnason T. Male Hypogonadism and Osteoporosis: The effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Endocrinol. 2017; 2017: 4602129. doi: 10.1155/2017/4602129. doi: 10.1155/2017/4602129.

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(s1):1-46. doi: 10.4158/GL-2020-0524SUPPL

Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: Excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380-90. doi: 10.7326/0003-4819-152-6-201003160-00008

Medina OA, Rosero OÓ, Rueda PPN, Sánchez EF, Chalem CM, González RMA, et al. II Consenso colombiano para el manejo de la

osteoporosis posmenopáusica. Rev Colomb Reumatol. 2018; 25(3): 184-210. Doi: 10.1016/j.rcreu.2018.02.006

Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone a controlled clinical trial. JAMA Intern Med. 2017;177(4):471-9. doi: 10.1001/jamainternmed.2016.9539

Rodríguez-Sanz M, Pineda-Moncusí M, Servitja S, Garcia-Giralt N, Martos T, Tusquets I, et al. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort. Bone. 2016; 92: 1-8. Doi: 10.1016/j.bone.2016.08.008

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019; 37(5): 423-438. doi: 10.1200/JCO.18.01160.

Trémollieres FA, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, et al. Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas [Internet]. 2017;95:65-71. Doi: 10.1016/j.maturitas.2016.10.007

Fraenkel M, Novack V, Mizrakli Y, Koretz M, Siris E, Norton L, et al. Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study. NPJ Breast Cancer. 2022; 8(1): 21. doi: 10.1038/s41523-022-00388-z.

Martínez P, Galve E, Arrazubi V, Sala MÁ, Fernández S, Pérez CE, et al. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors. Reumatol Clin. 2019;15(4):211-7. doi: 10.1016/j.reuma.2017.08.005

Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016; 374(3): 254-62. doi: 10.1056/NEJMcp1513724

Hone T, Macinko J, Millett C. Revisiting Alma-Ata: what is the role of primary health care in achieving the Sustainable Development Goals? Lancet. 2018;392(10156):1461-72. Doi: 10.1016/S0140-6736(18)31829-4

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Interdisciplinary Journal of Epidemiology and Public Health

Downloads

Download data is not yet available.